Nutriband Inc. Secures U.S. Patent for AVERSA(TM) Technology to Combat Drug Abuse

Nutriband Inc. (NASDAQ: NTRB) has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, enhancing its domestic intellectual property coverage. This innovation is specifically designed to mitigate the misuse, abuse, and accidental exposure of transdermal drugs with high abuse potential, such as fentanyl. Amidst the relentless opioid crisis in the U.S., where over 100,000 Americans succumb to drug overdoses annually, Nutriband's technology presents a promising avenue to bolster drug safety across various therapeutic categories.

The opioid epidemic continues to challenge public health systems, with synthetic opioids like fentanyl driving a significant portion of overdose deaths. Nutriband's AVERSA(TM) technology represents a proactive approach to drug safety, focusing on the design of drug delivery systems to prevent abuse at the product level. This development underscores the pharmaceutical industry's ongoing efforts to reconcile the need for patient access to essential medications with the imperative of preventing abuse and ensuring safety.